Overview of the clinical pharmacokinetics of eldecalcitol, a new active vitamin D3 derivative

Masaichi Abe, Naoki Tsuji, Fumiaki Takahashi, Yusuke Tanigawara

研究成果: Review article査読

12 被引用数 (Scopus)

抄録

Eldecalcitol, which was developed by Chugai Pharmaceutical Co., Ltd. as a treatment with the potential of becoming the drug of first choice for osteoporosis, is a new derivative of active vitamin D3 (1,25(OH) 2D3) with a hydroxypropyloxy group introduced at the 2β position. The clinical development of this product has included a Phase I multiple dose study, early and late Phase II studies, a Phase III study, a clinical pharmacology study to investigate pharmacokinetics in postmenopausal women, a drug interaction study, a bioequivalence formulation study and a clinical pharmacology study to investigate pharmacokinetics in patients with impaired liver function. Using data from all these studies, we sought to characterize the pharmacokinetic profile of eldecalcitol.

本文言語English
ページ(範囲)261-274
ページ数14
ジャーナルJapanese Pharmacology and Therapeutics
39
3
出版ステータスPublished - 2011 3 1

ASJC Scopus subject areas

  • 薬理学
  • 薬理学(医学)

フィンガープリント

「Overview of the clinical pharmacokinetics of eldecalcitol, a new active vitamin D<sub>3</sub> derivative」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル